Tepnel raises fresh funds and scales up research and development:
This article was originally published in Clinica
Executive Summary
Tepnel Life Sciences, the UK developer of DNA diagnostics, has raised £9.1 million ($14.6 million) net in a rights issue. The company reported after reporting turnover of £134,000 mainly from sales of its Faras antibiotic testing kits in the six months to December 1996. The company's net loss rose 30% to £650,000 after the scale-up of R&D. Some 15 Daras instruments are scheduled for delivery in April for testing.